Bulk Inquiry
Sorafenib tosylate
- BAY 43-9006 - Nexavar
- Parent CAS: 284461-73-0
- Soluble in DMSO
- MF: C21H16ClF3N4O3.C7H8O3S
- MW: 637.03
Description
Sorafenib tosylate is an orally active multikinase inhibitor that targets RAF kinases as well as pro-angiogenic receptor tyrosine kinases including VEGFR and PDGFR.
Sorafenib inhibits RAF–MEK–ERK signaling and tumor angiogenesis, linking direct antiproliferative effects with vascular pathway suppression. It is used in oncology research to study multikinase pharmacology, pathway adaptation and resistance.
Key Features
- Multikinase inhibitor of RAF and angiogenic RTKs
- Suppresses RAF–MEK–ERK pathway signaling
- Inhibits VEGFR- and PDGFR-dependent angiogenesis
- Clinically validated antineoplastic pharmacology
Applications
- RAF kinase and MAPK pathway studies
- Angiogenesis and VEGFR signaling assays
- Tumor-cell proliferation models
- Multikinase resistance and combination research
More Information
| Parent CAS No. | 284461-73-0 |
|---|---|
| Chemical Name | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
| SMILES | N1C=CC(OC2C=CC(NC(=O)NC3C=C(C(F)(F)F)C(Cl)=CC=3)=CC=2)=CC=1C(=O)NC.C1C=C(C)C=CC=1S(O)(=O)=O |
| MFCD | MFCD08235032 |
| InChi | InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10) |
| InChiKey | IVDHYUQIDRJSTI-UHFFFAOYSA-N |
| CID | 406563 |
| Short Description | Raf inhibitor |
References
- SM Wilhelm et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004, 64, 7099-7109.
- SM Wilhelm et al. The novel Raf inhibitor Bay 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lines. Proc. Am. Assoc. Cancer Res. 2003, 44, 106609.
- S. S. Sridhar et al. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005, 4, 677-685.
- S. S. Sridhar et al. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005, 4, 677-685.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1459 | GDC 0879 |
From $77.00 |
| 1474 | PLX 4720 |
From $55.00 |
| 1545 | AZ 628 |
From $88.00 |
| 1624 | PLX 4032 |
From $66.00 |
| 1984 | GW 5074 |
From $93.50 |
| 2438 | Cuspin-1 |
From $104.50 |
| 2504 | SB 590885 |
From $104.50 |
| 2590 | Locostatin |
From $66.00 |
| 2817 | RAF709 |
From $132.00 |
| 3067 | Belvarafenib |
From $126.50 |
| 3351 | Sorafenib |
From $66.00 |
| 3556 | LXH254 |
From $198.00 |
| 3862 | BGB-283 |
From Inquiry |
| 4033 | TAK-632 |
From Inquiry |
